

Form PTO 449

U.S. Department of Commerce  
Patent and Trademark OfficeATTY. DOCKET NO.  
**P51160**SERIAL NO.  
**09/912,483****INFORMATION DISCLOSURE STATEMENT BY  
APPLICANT***(Use several sheets if necessary)*APPLICANT  
**Erskine, et al.**FILING DATE  
**July 25, 2001**GROUP  
**1614****U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<b>QAT</b>	AA	3,133,061	05-1964	Kirchner, F. K.			
	AB	4,108,998	08-1978	Demerson, et al.			
	AC	5,426,224	06-1995	Lee, et al.			
	AD	6,063,801	05-2000	LaVoie, et al.			
	AE	6,174,678	01-2001	Menzei, et al.			
	AF	SN 09/912,610	07-2001	Erskine, et al.			
	AG	SN 10/199,933	07-2002	Erskine, et al.			
	AF	SN 60/391,700	26 June 2002	Axten, et al.			
<b>QAT</b>	AG	SN 60/391,710	26 June 2002	Axten, et al.			

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>QAT</b>	BA	WO/0043383	17 Jan 2000	PCT				
	BB	WO/0078748	13 June 2000	PCT				
	BC	WO/0208224	25 July 2001	PCT				
	BD	WO/107432	17 July 2000	PCT				
	BE	WO/107433	17 July 2000	PCT				
	BF	WO/224684	19 Sept 2001	PCT				
	BG	WO/0250040	19 Dec 2001	PCT				
	BH	WO/0256882	22 Jan. 2002	PCT				
	BI	WO/02/096907	25 May 2001	PCT				
	BJ	WO/02/096907	25 May 2001	PCT				
	BK	PCT/EP02/05708	25 May 2001	PCT				
	BL	WO/03/010138	26 July 2001	PCT				
	BM	PCT/EP03/00824	29 Jan. 2002	PCT				
<b>QAT</b>	BN	PCT/EP03/00823	29 Jan 2002	PCT				

**RECEIVED****JUN 17 2003****OFFICE OF PETITIONS****OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

<b>QAT</b>	CA	Le Bras et al. "La Détermination de la Chimosensibilité de Plasmodium Falciparum" (1987) Annales de Pédiatrie, 34(5), 349-356.
<b>QAT</b>	CB	Girault et al., "Antimalarial, Antitrypanosomal, and Antileishmanial Activities and Cytotoxicity of Bis (9-amino-6-chloro-2-methoxyacridines): Influence of the Linker" (2000) J. Med. Chem., 43(14), 2646-2654.
EXAMINER <b>James Blum</b>		DATE CONSIDERED <b>7/17/03</b>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

DEC 03 2001

Sheet 1 of 2

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeATTY. DOCKET NO.  
P51113SERIAL NO.  
09/912,610INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT  
Erskine, et al.FILING DATE  
July 25, 2001GROUP  
Unknown

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
2	JW	AA	WO 00/21952	20.04.00	PCT			
2	JW	AB	WO 99/37635	29.07.99	PCT			
2	JW	AC	WO 00/21948	20.04.00	PCT			

RECEIVED


JUN 17 2003

OFFICE OF PETITIONS

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JW	AD	Couturier, et al., "Bacterial death by DNA gyrase poisoning", <i>Trends in Microbiology</i> , 6(7): 269-275 (1998).
JW	AE	Y. Pommier, "Diversity of DNA topoisomerases I and inhibitors", <i>Biochimie</i> , 80: 255-270 (1998).
JW	AF	Smith, et al., "Quinazoline Derivatives. II. Synthesis of 4-(4'-Diethylamino-1'-methylbutyl-amino)-6-methoxyquinazoline (SN 12,253)", <i>Journal of American Chemical Society</i> , 68: 1301-1303 (1946).
JW	AG	R.B. Merrifield, "Solid Phase Peptide Synthesis. I. the Synthesis of a Tetrapeptide", <i>Journal of American Chemical Society</i> , 85: 2149-2154 (1963).
JW	AH	Neil Osheroff, "Eukaryotic Topoisomerase II Characterization of Enzyme Turnover", <i>The Journal of Biological Chemistry</i> , 261(21): 9944-9950 (1985).
JW	AI	Drlica, et al., "DNA Gyrase, Topoisomerase IV, and the 4-Quinolones", <i>Microbiology and Molecular Biology Reviews</i> , 61(3): 377-392 (1997).
JW	AJ	Neil Osheroff, "Biochemical Basis for the Interactions of Type I and Type II Topoisomerases with DNA", <i>Pharmacology &amp; Therapeutics</i> , 41: 223-241 (1989).
JW	AK	D'Incalci, et al., "DNA-topoisomerase inhibitors", <i>Current Opinions in Oncology</i> , 5: 1023-1028 (1993).
JW	AL	Capranico, et al., "DNA sequence selectivity of topoisomerases and topoisomerase poisons", <i>Biochimica et Biophysica Acta</i> , 1400: 185-194 (1998).
JW	AM	Wessel, et al., "Human Small Cell Lung Cancer NYH Cells Selected for Resistance to the Bisdioxopiperazine Topoisomerase II Catalytic Inhibitor ICRF-187 Demonstrate a Functional R162Q Mutation in the Walker A Consensus ATP Binding Domain of the $\alpha$ Isoform", <i>Cancer Research</i> , 59: 3442-3450 (1999).
JW	AN	Hiasa, et al., "Topoisomerase IV Can Support <i>oriC</i> DNA Replication in Vitro", <i>The Journal of Biological Chemistry</i> , 269(23): 16371-16375 (1994).


09 Apr 03



Sheet 2 of 2

<b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b>  (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P51113	SERIAL NO. 09/912,610
	APPLICANT Erskine, <i>et al.</i>		
	FILING DATE July 25, 2001	GROUP <del>Unknown</del> 1651	

AO	Fortune, <i>et al.</i> , "Merbarone Inhibits the Catalytic Activity of Human Topoisomerase II $\alpha$ by Blocking DNA Cleavage", <i>The Journal of Biological Chemistry</i> , 273(28): 17643-17650 (1998).
AP	Chini, <i>et al.</i> , "Regioalternating Selectivity in the Metal Salt Catalyzed Anionolysis of Styrene Oxide", <i>Journal of Organic Chemistry</i> , 56: 5939 - 5942 (1991).
AQ	Anthony Maxwell, "Protein gates in DNA topoisomerase II", <i>Nature Structural Biology</i> , 3(2): 109-112 (1996).
AR	Nishibata, <i>et al.</i> , "Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation.", <i>Tetrahedron</i> , 47(43): 8985-8990 (1991).
AS	Olland, <i>et al.</i> , "Catalysis of ATP Hydrolysis by Two NH <sub>2</sub> -terminal Fragments of Yeast DNA Topoisomerase II", <i>The Journal of Biological Chemistry</i> , 274(31): 21688 - 21694 (1999).
AT	Roca, <i>et al.</i> , "Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp", <i>Proceedings of the National Academy of Sciences USA</i> , 91: 1781 - 1785 (1994).
AU	Stingl, <i>et al.</i> , "Process for the preparation of 2-(S)-piperazinecarboxylic acid by continuous resolution via diastereomeric salt pairs", <i>Tetrahedron: Asymmetry</i> , 8(7): 979-982 (1997).
AV	Anthony Maxwell, "DNA gyrase as a drug target", <i>Trends in Microbiology</i> , 5(3): 102 - 109 (1997).
AW	Critchlow, <i>et al.</i> , "DNA Cleavage Is Not Required for the Binding of Quinolone Drugs to the DNA Gyrase-DNA Complex", <i>Biochemistry</i> , 35: 7387 - 7393 (1996).
AX	Capranico, <i>et al.</i> , "DNA topoisomerase II poisons and inhibitors", <i>Cancer Chemotherapy and Biological Response Modifiers Annual 17</i> , Elsevier Science, Chapter 6, pp. 114-131 (1997).

EXAMINER 	DATE CONSIDERED 09 Apr 03
-------------------------------------------------------------------------------------------------	------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

N:\ERG\APPS\VP51160\1449.doc

RECEIVED

JUN 17 2003

OFFICE OF PETITIONS